Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. (symbol: VERU) is a comprehensive biopharmaceutical company dedicated to advancing treatments in men’s and women’s health, as well as oncology. The company specializes in developing and commercializing innovative pharmaceuticals and medical devices.
Veru operates through three divisions:
- Pharmaceuticals and Devices: This division focuses on treatments for conditions such as benign prostatic hyperplasia, male infertility, prostate cancer, gout, sexual dysfunction, and side effects of hormonal therapies in men. For women's health, Veru is developing treatments targeting female sexual health and advanced breast and ovarian cancers.
- Consumer Health Products: This division includes the marketing and distribution of the FC2 Female Condom, the only FDA-approved female condom that offers dual protection against sexually transmitted infections, including HIV/AIDS and unintended pregnancies. Since its introduction, FC2 has been distributed to 144 countries.
- Public Sector: Veru collaborates with international health organizations, including ministries of health and the U.N., to improve global health outcomes. The company supplies large-scale tenders, such as a multi-year contract with the South African government for FC2.
Veru is currently in late-stage development for several pivotal pharmaceuticals:
- Enobosarm: A novel selective androgen receptor modulator (SARM) being developed to enhance fat loss while preserving muscle mass in overweight or obese patients receiving GLP-1 RA drugs. Enobosarm is also under investigation for treating metastatic breast cancer.
- Sabizabulin: A microtubule disruptor in Phase 3 clinical trials aimed at treating viral-induced acute respiratory distress syndrome (ARDS), particularly in hospitalized COVID-19 patients.
Recent achievements include the FDA's clearance for a Phase 2b clinical study of enobosarm, marking significant progress in its weight loss and muscle preservation programs. The company has also initiated the enrollment of patients for this study, with results expected by the end of 2024, and a follow-up study expected to complete by mid-2025.
Financially, Veru is committed to ensuring robust funding for its ongoing projects. Recent financial updates reveal successful financing rounds and strategic partnerships, positioning the company well for future growth and development. The company is also actively working to regain compliance with Nasdaq listing requirements following delays in its SEC filings.
Veru Inc. (NASDAQ: VERU) announces positive Phase 2 clinical trial results for VERU-111, an oral treatment for hospitalized COVID-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS). The trial showed an 81% relative reduction in death or respiratory failure at Day 29 and 82% relative decrease in mortality compared to placebo. Patients receiving VERU-111 had fewer ICU days and mechanical ventilation needs. The company aims for a Phase 3 trial to start in April 2021, with a focus on regulatory discussions with the FDA.
Veru Inc. (NASDAQ: VERU) will release its fiscal 2021 first quarter financial results on February 10, 2021, before market opening. A conference call will be held at 8 a.m. ET on the same day to discuss the company’s performance and answer questions. Veru focuses on oncology, developing treatments for prostate and breast cancer, including clinical trials for its drug candidates VERU-111 and VERU-100. The company is also advancing multiple clinical trials across its pipeline and will provide insights into future developments during the call.
Veru Inc. announced a significant breakthrough in breast cancer research, revealing the androgen receptor acts as a tumor suppressor in ER+ breast cancer. Preclinical studies indicate that enobosarm, a selective androgen receptor agonist, shows potent antitumor activity in resistant cases. The Phase 3 ARTEST study for enobosarm is set to commence next quarter, targeting patients resistant to existing therapies. This research could change treatment approaches and emphasizes enobosarm's potential without unwanted side effects, marking a new era in breast cancer treatment.
Veru Inc. (NASDAQ: VERU) announced its participation in the H.C. Wainwright Bioconnect 2021 Conference, with an on-demand presentation available from January 11-14, 2021. The webcast will also be archived for 90 days. Veru focuses on oncology, developing treatments for prostate and breast cancer, including investigational drugs such as VERU-111, VERU-100, and enobosarm. The company plans to advance various clinical trials throughout 2021.
Veru Inc. (NASDAQ: VERU) announced promising results from its Phase 2 clinical trial for enobosarm, focused on ER+/HER2- metastatic breast cancer. Highlighted as a Spotlight Presentation at the 2020 San Antonio Breast Cancer Symposium, enobosarm showed a clinical benefit rate of 32% in a 136-patient cohort. The FDA has approved a Phase 3 ARTEST study, set to begin in Q2 2021, to further evaluate enobosarm's efficacy against active comparators in similar patient populations. This novel therapy offers hope for patients who have exhausted other treatment options.
Veru Inc. (NASDAQ: VERU) presented promising preclinical data for VERU-111, showing its potential in treating triple negative breast cancer (TNBC) resistant to paclitaxel. Findings from the 2020 San Antonio Breast Cancer Symposium revealed that VERU-111 significantly inhibited tumor growth in both paclitaxel-sensitive and resistant models. The company plans to engage with the FDA in early 2021 to discuss advancing VERU-111 into a Phase 2b clinical trial for women with taxane-resistant TNBC, potentially leading to accelerated approval.
Veru Inc. (NASDAQ: VERU) has completed its transformation into a late-stage oncology biopharmaceutical company focused on prostate and breast cancer therapies. It has licensed worldwide rights to enobosarm, an oral androgen receptor targeting agent for endocrine-resistant ER+ HER2- metastatic breast cancer. Veru plans to initiate four registration trials in 2021, including the ARTEST trial for enobosarm and studies for VERU-111 and VERU-100. The company expects to fund these trials through existing resources without the need for new equity financing until at least FY 2022.
Veru Inc. (NASDAQ: VERU) reported record financial results for fiscal 2020, with net revenues rising 34% to $42.6 million and gross profit increasing 42% to $30.8 million. Notably, FC2 prescription sales surged 93% to $27.1 million. Despite a net loss of $19 million, which included a $14.1 million non-cash impairment charge, adjusted operating loss improved significantly. The company completed the $20 million sale of its PREBOOST business and anticipates that current cash and operational cash flow will support drug development through at least fiscal 2022. Key clinical trials are advancing, including a late-stage breast cancer drug entering Phase 3.
Veru Inc. (NASDAQ: VERU) will report its fiscal 2020 fourth quarter and year results on December 9, 2020, before the market opens. Management will host a conference call at 8 a.m. ET to discuss performance and answer questions. Veru focuses on developing novel medicines for prostate cancer, including VERU-111 and VERU-100. The company is advancing multiple clinical studies and expects to begin a Phase 2 trial for VERU-100 in Q1 2021 and submit the NDA for TADFYN® early next year.
Veru Inc. (NASDAQ: VERU) announced its participation in four upcoming healthcare investor conferences, aimed at discussing its innovative biopharmaceutical solutions for prostate cancer management. The conferences include the Morgan Stanley Virtual Healthcare Conference from September 14-18, 2020, and the Cantor Fitzgerald Global Healthcare Conference on September 15-17, where Veru will present on September 15 at 8:00 a.m. ET. Additionally, the company will present at the H.C. Wainwright Conference on September 16 and the Oppenheimer Summit on September 21, with a focus on its pipeline products, including VERU-111 and VERU-100.
FAQ
What is the current stock price of Veru (VERU)?
What is the market cap of Veru (VERU)?
What does Veru Inc. specialize in?
What are the main divisions of Veru Inc.?
What is the FC2 Female Condom?
What is enobosarm?
What is sabizabulin?
What recent FDA clearance did Veru receive?
What are Veru’s recent financial highlights?
Has Veru faced any compliance issues recently?
What is Veru’s role in global health?
What are the expected timelines for Veru’s clinical trials?
